Cite
Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer.
MLA
Otsubo, K., et al. “Development of Leptomeningeal Carcinomatosis during a Marked Response of Brain Metastases to Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.” Annals of Oncology, vol. 29, no. 3, Mar. 2018, pp. 780–81. EBSCOhost, https://doi.org/10.1093/annonc/mdx700.
APA
Otsubo, K., Seki, N., Nakanishi, Y., & Okamoto, I. (2018). Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer. Annals of Oncology, 29(3), 780–781. https://doi.org/10.1093/annonc/mdx700
Chicago
Otsubo, K, N Seki, Y Nakanishi, and I Okamoto. 2018. “Development of Leptomeningeal Carcinomatosis during a Marked Response of Brain Metastases to Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.” Annals of Oncology 29 (3): 780–81. doi:10.1093/annonc/mdx700.